An enzyme replacement for Morquio A (MPS IVA)
Elosulfase alfa
An enzyme replacement given by drip into a vein to treat Morquio A syndrome (MPS IVA).
What is Elosulfase alfa?
Elosulfase alfa is a specialist enzyme replacement medicine used to treat Morquio A syndrome, also called mucopolysaccharidosis type IVA (MPS IVA), a rare inherited condition in which a missing enzyme lets certain complex sugars build up and damage bones, joints and other tissues. It supplies a working form of the enzyme, given as a drip into a vein on a regular basis. The most important thing to know is the risk of infusion-related and allergic-type reactions, which the team watches for closely. It does not reach the brain.
Education and reference only. This is a plain-language guide to Elosulfase alfa — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Elosulfase alfa is an enzyme replacement therapy used to treat Morquio A syndrome (MPS IVA), a rare inherited disorder. In this condition the body lacks a working copy of an enzyme that breaks down certain complex sugar molecules (glycosaminoglycans), so these build up and particularly affect the bones, joints, heart and other tissues. Elosulfase alfa is a laboratory-made version of the missing enzyme, given as a drip (infusion) into a vein, usually under specialist care. It is a long-term, regular treatment aimed at the effects of the disorder rather than a cure.
How it works
In Morquio A syndrome, a missing or faulty enzyme means certain complex sugars cannot be broken down, so they accumulate in tissues, especially affecting the skeleton, and cause progressive damage. Elosulfase alfa supplies a working form of this enzyme, which cells take up and use to help clear the build-up, easing some of the effects on the body such as physical stamina. Because the enzyme is used up over time, it has to be given regularly by infusion to keep working. Like other enzyme treatments given into the body, it does not cross into the brain.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist enzyme medicine given by drip in the UK to treat Morquio A syndrome (mucopolysaccharidosis type IVA).
Practical use
How to take Elosulfase alfa
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Receive it as a drip (infusion) into a vein on the regular schedule your specialist team arranges.
- Have infusions in a setting where staff can watch for and manage any reaction.
- Take any medicines offered beforehand to reduce the chance of an infusion reaction, if advised.
- Tell the team straight away during an infusion if you feel unwell, itchy, flushed or short of breath.
- Keep to your regular infusion appointments, as this is a long-term, ongoing treatment.
Weighing it up
Advantages & disadvantages of Elosulfase alfa
Advantages
- Replaces the missing enzyme to help clear the harmful build-up in Morquio A syndrome.
- Can improve physical stamina and ease some effects of the condition over time.
- Provides a treatment for a very rare condition that otherwise has few options.
Disadvantages
- Can cause infusion-related and allergic-type reactions, sometimes serious.
- Needs regular drips into a vein over the long term.
- Does not reach the brain, so it does not treat effects on the nervous system.
Practical use
Good to know
The most important safety point with elosulfase alfa, as with other infused enzyme treatments, is the risk of reactions during or shortly after the drip. These infusion-related reactions can include fever, chills, headache, vomiting, a rash or itching, and, less commonly, more serious allergic-type (anaphylactoid) reactions, so infusions are given where staff and equipment are on hand to manage them, and the team often gives other medicines beforehand to reduce the risk. Treatment is long term and regular, meaning an ongoing commitment to infusions. It is also important to understand that it helps the effects of the condition on the body but does not cross into the brain, so the specialist team will explain what it can and cannot do. Care is shared across a specialist team experienced in this rare condition.
Who should not take it / use with caution
- People who have had a serious allergic reaction to elosulfase alfa should not receive it, unless carefully reassessed by the specialist team.
- It is used with particular care in anyone who has had infusion reactions before, or who has breathing problems that reactions could worsen.
- It should only be given under specialist supervision in a suitable setting.
Monitoring
- Close observation during and after each infusion for reactions, including breathing.
- Regular review of how the condition, stamina and symptoms are responding over time.
- Watching for allergic-type reactions and, where relevant, tests linked to the immune response.
Side effects
- Infusion-related reactions such as fever, chills, headache, vomiting, rash or itching.
- Less commonly, more serious allergic-type (anaphylactoid) reactions, which need immediate treatment.
- Tummy pain, nausea or feeling generally unwell in some people.
- Breathing symptoms during an infusion in some people, which the team watches for closely.
Key interactions
- There are few well-established routine medicine interactions, but tell your team about all your medicines.
- Medicines may be given before an infusion to reduce the chance of a reaction.
- Any past infusion or allergic reaction is important information for the team.
Available as: A solution given as a drip (infusion) into a vein.
Answers
Elosulfase alfa: frequently asked questions
What is elosulfase alfa used for?
It is an enzyme replacement therapy used to treat Morquio A syndrome (MPS IVA), a rare inherited disorder, by supplying a working form of the missing enzyme.
How is it given?
It is given as a drip (infusion) into a vein on a regular basis, under specialist care, as a long-term treatment.
What are the main risks?
The main risk is reactions during or after the drip, including allergic-type and breathing reactions, so infusions are given where staff can manage them.
Does it treat the brain effects?
No. Because the enzyme does not cross into the brain, it does not treat the effects of the condition on the nervous system.
Is it a cure?
No. It helps clear the harmful build-up and can ease some effects on the body, but it is a long-term treatment rather than a cure.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.